Prime Medicine, Inc. (PRME) vs SOPHiA GENETICS S.A. (SOPH)
A side-by-side comparison of Prime Medicine, Inc. and SOPHiA GENETICS S.A. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
PRME
Prime Medicine, Inc.
$3.52HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
SOPH
SOPHiA GENETICS S.A.
$7.40HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — PRME vs SOPH
growth of $100 · dividends reinvested · last 4yPRME -79.1% (-32.4%/yr)SOPH +261.2% (+37.9%/yr)SOPH compounded faster over this window
Log scale — wide-divergence pair
PRME SOPH
PRME vs SOPH: by the numbers
- •PRME is the larger company ($636M vs $621M market cap).
- •Both run net losses; SOPH's is the smaller (-93.86% vs -4613.11% net margin).
- •SOPH grew revenue faster over the past five years (20.33% vs -2.32% CAGR).
Metrics side by side
Valuation
| Metric | PRME | SOPH |
|---|---|---|
| P/S ratio | 156.27 | 7.20 |
| P/B ratio | 15.99 | 7.47 |
Profitability
| Metric | PRME | SOPH |
|---|---|---|
| Gross margin | -58.05% | 66.63% |
| Operating margin | -4498.06% | -85.01% |
| Net margin | -4613.11% | -93.86% |
| ROE | -471.98% | -97.31% |
| ROIC | -90.42% | -49.73% |
Growth (annualized)
| Metric | PRME | SOPH |
|---|---|---|
| Revenue CAGR (5Y) | -2.32% | 20.33% |
| Total return CAGR (5Y) | N/A | -13.62% |
Frequently asked
- Which has grown faster, PRME or SOPH?
- Over the past five years, SOPH grew revenue faster — PRME at a -2.32% CAGR versus SOPH at 20.33%.
Go deeper
Dig into the metrics
Prime Medicine ROESOPHiA GENETICS ROEPrime Medicine operating marginSOPHiA GENETICS operating marginPrime Medicine revenue growthSOPHiA GENETICS revenue growthPrime Medicine free cash flowSOPHiA GENETICS free cash flow
Prime Medicine & SOPHiA GENETICS appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.